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Abstract
A growing body of evidence indicates that resolution of acute inflammation is an active 
process1,2. Resolvins are a new family of lipid mediators enzymatically generated within 
resolution networks that possess unique and specific functions to orchestrate catabasis2,3. 
Resolvin D2 (RvD2) was originally identified in resolving exudates, yet its individual contribution 
in resolution remained to be elucidated. Here, we established RvD2’s potent stereoselective 
actions in reducing excessive neutrophil trafficking to inflammatory loci. RvD2 decreased 
leukocyte:endothelial interactions in vivo by endothelial-dependent nitric oxide production, and 
direct modulation of leukocyte adhesion receptor expression. In microbial sepsis initiated by cecal 
ligation and puncture (CLP), RvD2 sharply decreased both local and systemic bacterial burden, 
excessive cytokine production and neutrophil recruitment, while increasing peritoneal 
mononuclear cells and macrophage phagocytosis. These multi-level pro-resolving actions of RvD2 
translate to increased survival from CLP-induced sepsis and surgery. Together, these results 
identify RvD2 as a potent endogenous regulator of excessive inflammatory responses that acts via 
multiple cellular targets to stimulate resolution and preserve immune vigilance.
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Ungoverned inflammation is an underlying component of many pathologies, such as 
cardiovascular disease, diabetes and sepsis4,5. It’s now recognized that resolution of 
inflammation is an active program controlled by temporal and spatial production of 
specialized chemical mediators2,3,6. Recently, autacoids endogenously generated from 
omega-3 essential fatty acids, namely resolvins, were identified during the resolution phase 
of inflammation that actively promote catabasis via potent pro-resolving and anti-
inflammatory actions2,3. Resolvin D2 (RvD2), biosynthesized from docosahexaenoic acid 
(DHA), was originally identified during resolution3. Its complete stereochemistry and 
actions remained of interest. To this end, we investigated whether RvD2 preserves host 
immune function to facilitate resolution of inflammatory sepsis.
First, the complete stereochemistry of endogenous RvD2 was determined by physical 
matching with compounds prepared by total organic synthesis (Fig. S1a) from 
enantiomerically and geometrically pure starting materials in accordance with the basic 
structure determined in resolving exudates3 (Fig. 1). This approach was needed because the 
nanogram amounts of endogenous RvD2 isolated precluded direct NMR analysis. The 
double bond geometry of synthetic material was validated by 1H NMR (Fig. S1b). The 
biosynthesis of RvD2 involves 17-lipoxygenation of DHA to 17S-hydroperoxy-4Z, 7Z, 10Z, 
13Z, 15E, 19Z-docosahexaenoic acid (17-HpDHA) that’s enzymatically transformed to a 
7(8)epoxide-containing intermediate3,7 in human leukocytes. This enzymatic activity 
involves 5-lipoxygenase (LOX) and its epoxide generating activity 8. These steps can occur 
within a single cell type or via transcellular biosynthesis. For example, eosinophils, rich in 
15-LOX, can convert DHA to 17-HpDHA that PMN can convert to RvD2 (Fig. 1a). 
Actively phagocytosing polymorphonuclear neutrophils (PMN) converted resolvin precursor 
17-HpDHA to RvD2 as determined by LC-MS/MS-based lipidomics. A total ion 
chromatogram (m/z 375 [M-H]) of human leukocyte-derived RvD2 is shown (Fig. 1b), with 
characteristic conjugated tetraene UV-chromophore (λmax at 301nm with shoulders at 289 
and 315). Synthetic material showed an exclusive and prominent peak with retention time 
(RT) and UV-spectrum essentially identical to leukocyte-derived RvD2 (Fig. 1c). Co-
injection of synthetic and leukocyte-derived RvD2 led to an increase in intensity and co-
elution (Fig. 1d). To further establish the physical properties, their tandem mass spectra 
(MS) were analyzed, with essentially identical MS fragmentation, and diagnostic ions in 
agreement with original assignments for endogenous RvD2 (Fig. 1e & f)3. To validate the 
biosynthetic pathway, activated human PMN were incubated with deuterium labelled 17S-
HpDHA-d5 or DHA-d5; RvD2 containing the d5 label was biosynthesized (Fig. 1g), the 
parent ion increased to m/z 380 [M-H], and neutral loss ions reflective of d5-containing 
fragments (Fig. S2). Next, to further confirm the structural assignment, derivatized RvD2 
was subjected to GC/MS. Derivatized RvD2 C-value was 25.2 ± 0.1 and its spectrum (Fig. 
S3) showed diagnostic ions at m/z 479, 435, 229 and 1713. Collectively, matching of 
synthetic and leukocyte-derived RvD2 (by RT, diagnostic MS ions and derivatization) 
established the complete stereochemistry and double bond geometry of endogenous RvD2 as 
7S, 16R, 17S-trihydroxy-4Z, 8E, 10Z, 12E, 14E, 19Z-docosahexaenoic acid.
RvD2 displayed potent actions in microbial peritonitis, with a drastic ~70% reduction in 
zymosan-stimulated PMN infiltration at doses as low as 10 pg (Fig. 2). Importantly, Δ10-
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trans-RvD2 isomer was essentially inactive, indicating that specific geometry of endogenous 
RvD2 is required for bioactivity. To determine whether RvD2 decreases leukocyte-
endothelial interactions, cremasteric microcirculation was analyzed. Platelet activating 
factor (PAF; 100 nM)6,9 superfusion caused increased leukocyte adherence and emigration 
that was markedly reduced by 1 nM RvD2 (Fig. 2c & d). Representative microcirculation 
before and after RvD2 superfusion are in supplementary movies. These potent RvD2 actions 
were recapitulated with human cells to identify potential cellular directed actions (i.e. 
endothelial cells and PMN). RvD2 potently reduced PAF-stimulated capture and adhesion of 
PMN by HUVECs under flow (Fig. S4)10. Noteworthy, RvD2 also reduced complement-
mediated (C5a) PMN:endothelial interactions (Fig. S5a–c), a key mediator in sepsis11. 
Consistent with the impact of RvD2 on leukocyte:endothelial interactions, RvD2 diminished 
PAF-stimulated CD62L shedding on isolated human PMN, and CD18 surface expression 
(Fig. 2e & f). RvD2 alone did not alter PMN adhesion molecule expression (n=3 not 
shown). To obtain further evidence for direct actions of RvD2 on human leukocytes, we 
monitored reactive oxygen species (ROS). Importantly, RvD2 did not stimulate extracellular 
superoxide, while it potently reduced C5a-stimulated extracellular superoxide generation 
(Fig. S5e & f).
Next, we assessed the contribution of nitric oxide (NO), an established anti-adhesive 
mediator12,13 in RvD2-reduced leukocyte adherence in post-capillary venules. The non-
selective nitric oxide synthase inhibitor, L-NAME, before addition of RvD2 partially 
reversed the decreased leukocyte adherence and emigration (Fig. 3a & b). To obtain 
additional evidence for NO generation by RvD2 in vivo, vascular fluorescence was 
monitored (see Methods). Topical administration of RvD2 (100 pg/ear) increased 
fluorescence intensity, whereas lower doses (1 and 10 pg) were ineffective (Fig. S6a). L-
NAME given before topical RvD2 application abolished this response (Fig. S6b), indicating 
that RvD2-stimulated vascular responses at this dose were NO-dependent. Of note, i.v. 
injection of RvD2 at doses that inhibited PMN infiltration in peritonitis (10 pg) did not 
increase fluorescence intensity indicating that only local elevated doses of RvD2 stimulated 
vascular responses (not shown). Additionally, RvD2 superfusion (1 nM) did not cause an 
increase in vascular permeability (Fig. S6e). Topical RvD2 (10 or 100pg) did not induce 
leukocyte infiltration into ear skin compared to chemoattractant leukotriene B4 (Fig. S6f). 
These results demonstrate that high focal delivery of RvD2 stimulates rapid NO production 
consistent with its anti-adhesive effects but not to a level that is pro-inflammatory. 
Corroboratory results were obtained with HUVECs whereby RvD2 dose-dependently 
stimulated NO generation (Fig. 3c), suggesting topical actions were likely mediated via 
endothelial nitric oxide synthase (eNOS). To test this, peritonitis was evaluated in eNOS−/− 
mice. In concurrence with an earlier report14, no changes were observed with respect to 
leukocyte infiltration between wild type and eNOS−/− mice. RvD2 reduction in leukocytes 
was eliminated in eNOS−/− mice (Fig. 3d), an effect that has also been reported for aspirin 
and local aspirin-triggered lipoxins15. Notably, RvD2 also stimulated vasoprotective 
prostacyclin (6-keto-PGF1α; Fig. S7a), this dose-response proved bell-shaped like other 
lipid mediators1,2,6. RvD2-stimulated prostacyclin and NO were pertussis-toxin sensitive 
implicating a role for G-protein coupled receptor(s) (Fig. S7b & c). Thus, RvD2 regulates 
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leukocyte adherence via both direct actions on PMN (vide supra) and endothelial vasoactive 
substances.
Next, anti-inflammatory and pro-resolving actions of RvD2 were evaluated in cecal ligation 
and puncture (CLP), an established murine microbial sepsis that closely resembles human 
pathology16,17. Omega-3 fatty acids are beneficial in some inflammatory conditions, 
including sepsis18–20, although the mechanistic basis underlying protection is still 
emerging. To this end, RvD2 significantly reduced the amount of live aerobic bacteria in 
both blood and peritoneum at 12 h post-CLP, while Δ10-trans-RvD2 was essentially not 
active (Fig. 4a & b). This was associated with a significant reduction in total leukocytes and 
specifically, PMN infiltration into the peritoneum (Fig. 4c & d). Interestingly, the ratio of 
mononuclear cells to PMN was increased with RvD2 (Fig. 4d inset), similar to results 
obtained with sterile zymosan-stimulated peritonitis (Fig. S9a). Intraperitoneal delivery of 
RvD2 at 1h post-CLP also reduced both blood and peritoneal bacteria (Fig. S8). Given the 
role of macrophages in clearance of bacteria, cellular debris and apoptotic PMNs to facilitate 
inflammation-resolution1,2, RvD2 treatment promoted phagocyte-dependent bacterial 
clearance observed in inguinal lymph nodes (Fig. S10d). Evidence for direct macrophage 
actions were obtained in vitro, where RvD2 potently enhanced macrophage phagocytosis of 
opsonized-zymosan (Fig. S9b). To obtain additional evidence for this pro-resolution role of 
RvD2, cytokines were monitored during CLP both locally (peritoneum) and systemically 
(plasma). RvD2 drastically reduced levels of pro-inflammatory cytokines associated with 
poor outcomes in sepsis17, namely IL-6, IL-1β, IL-23 and TNF-α (Fig. 4e & S10a). RvD2 
reduced cytokine levels while enhancing bacterial clearance, a response also observed for 
macrophage scavenger receptor A21. Hence, it’s plausible that RvD2 prevents persistent 
amplification signals downstream of pattern-recognition receptors, dampening responses of 
classically activated macrophages22,23. RvD2 also drastically decreased IL-17, as well as 
IL-10, which is of interest in light of its detrimental impact on survival in sepsis24. Thus, 
RvD2 differs in action than lipoxin A4 which stimulates IL-1025. High levels of both pro- 
and anti-inflammatory cytokines, including IL-10, are predictive of early mortality in sepsis 
and diminishing IL-10 levels proved beneficial in sepsis26,27. Pro-inflammatory mediators, 
including prostaglandin E2 (PGE2) and LTB4 were also decreased in peritoneum by RvD2 
(Fig. 4f, g and Fig. S10b & c). Of interest, in addition to macrophage-directed actions, RvD2 
directly enhanced PMN E.coli phagocytosis that was accompanied by an increase in 
intracellular ROS (Fig. 4h & i). RvD2 does not possess direct antibacterial activity 
compared to ampicillin (Fig. S11). RvD2-treated CLP mice also showed protection at 12h 
post-CLP from hypothermia (Fig. 4j). Accordingly, RvD2 dramatically increased survival 
rates among CLP-operated mice (Fig. 4k) and activity levels12h post-CLP were resumed 
(Supplementary movie 3).
The present results establish the complete stereochemistry of endogenous RvD2 and its 
potent stereoselective actions facilitating resolution. Local and systemic bacterial burden in 
microbial sepsis were controlled and significantly dampened with RvD2. This potent D-
series resolvin protected from excessive leukocyte infiltration and overzealous cytokine 
production, as well as enhanced clearance of microbes, thus preventing sepsis-induced 
lethality. Sepsis remains a clinical challenge, with high mortality rates and increasing 
Spite et al. Page 4
Nature. Author manuscript; available in PMC 2010 April 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
prevalence5,28. Given the uncontrolled inflammatory pathogenesis of sepsis, anti-
inflammatory therapies are used for sepsis management in humans, but have ultimately 
failed due primarily to sustained immunosuppression5. Overall, these results indicate that 
RvD2 is a potent endogenous mediator which actively promotes resolution suggesting new 
therapeutic approaches that do not compromise host-defence.
Methods Summary
Intra-vital microscopy (IVM)
Experiments were approved by and performed under guidelines of the Ethical Committee 
for Use of Animals, Barts and The London School of Medicine and Home Office regulations 
(Guidance on the Operation of Animals, Scientific Procedures Act, 1986). IVM was used to 
observe actions of RvD2 on platelet activating factor (PAF; C16 form: C26H54NO7P; 100 
nM; Sigma (1h prior to RvD2;Time 0)) -stimulated leukocyte responses within the 
cremasteric microcirculation of C57 BL/6 mice. Mice were anesthetized with xylazine (7.5 
mg/kg) and ketamine (150 mg/kg), and cremaster prepared29. In some experiments, FITC-
albumin (1mg) was administered i.v. to assess vascular leakage.
Cecal ligation and puncture (CLP)
CLP was performed in male FVB mice16, in accordance with the Harvard Medical Area 
standing committee on animals protocol #02570. The cecum was ligated below the ileocecal 
valve for mid-grade sepsis16. A through and through puncture was performed with a 20 
gauge needle, followed by one additional puncture in the distal tip of the cecum. Mice 
received saline (500 µl s.c.) followed by i.v. administration of vehicle (0.1% ethanol), or 
RvD2 methyl ester (100 ng) at the time of puncture. In some experiments, RvD2-Me (1 µg) 
was administered i.p. 1h post-CLP. At 12h, rectal temperature was measured, blood 
collected by cardiac puncture and peritoneal exudates obtained. Blood and peritoneal 
bacteria levels were determined by growth on tryptic soy agar plates. Plasma and peritoneal 
cytokine levels were determined by Searchlight array (Woburn, MA). Peritoneal cells were 
differentiated using Wright-Giemsa staining.
Statistics
Data are mean ± s.e.m. Multiple group comparisons were made using one-way or two-way 
ANOVA followed by Dunnett’s or Bonferroni post tests where appropriate and direct 
comparisons made using a two-tailed unpaired Student’s t-test. Kaplan-Meier survival 
curves were analyzed using a one-tailed log-rank test. In all cases, a P value <0.05 was 
considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Stereochemical assignment, biosynthesis and total organic synthesis of RvD2
(a) Rv biosynthesis illustrating potential PMN, eosinophil transcellular biosynthesis. Ion 
chromatograms (m/z 375) depicting human leukocyte-derived RvD2 with UV spectrum and 
related isomers with the ω-2 OH metabolites of PD1 and 7,17 diHDHA. (b). RvD2 prepared 
by total organic synthesis (c) and (d) co-injection with leukocyte-derived RvD2. MS/MS of 
leukocyte-derived RvD2 (e) and synthetic RvD2 (f) with prominent ions at m/z 357 [M-H-
H2O], 339 [M-H-2H2O], 313 [M-H-CO2-H2O], 295 [M-H-CO2-2H2O], 277, 259 [277-
H2O], 247, 233 [277-CO2], 141 and 113. (g) Leukocyte-derived RvD2-d5. Representative of 
n=3–5.
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Figure 2. RvD2 potently reduces leukocyte-endothelial interactions to reduce microbial 
peritonitis
(a,b) Leukocyte infiltration in peritonitis. (b) Equidose comparison (100 pg) of RvD2 and 
Δ10-trans-RvD2. (c-d) Leukocyte trafficking in vivo. PAF(100 nM)-stimulated leukocyte 
adherence (c) and emigration (d) ± RvD2 or RvD1. (e-f) Adhesion receptor surface 
expression. Results (n=3–6) are mean ± s.e.m. *P<0.05, **P<0.01 (a, b), *P<0.01 (PAF vs. 
PAF + RvD2 1nM), #P<0.05 (PAF vs. PAF + RvD1 30nM) and ‡P<0.05 (PAF vs. PAF + 
RvD2 30nM) (c-d) ANOVA.
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Figure 3. Modulation of leukocyte trafficking by RvD2 is nitric oxide dependent
(a,b) Leukocyte trafficking in vivo. Cremasters were superfused with PAF (100 nM), L-
NAME (100 µM) and RvD2 (1 nM) and leukocyte adhesion (a) and emigration (b) was 
quantified (n=3–5). (c) Nitric oxide (NOx; nitrate/nitrite) generation in primary HUVECs 
incubated with RvD2 (n=4–6). (d) Zymosan-stimulated PMN infiltration after 
administration of RvD2 (100 ng; i.v.) in wild-type and eNOS−/− mice (n=3–5). Results are 
mean ± s.e.m., *P<0.05, ***P<0.001 two-way ANOVA (a,b), one-way ANOVA (c), two-
tailed unpaired Student’s t-test (d).
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Figure 4. RvD2 reduces bacterial levels, systemic inflammation and enhances survival in 
microbial sepsis
(a,b) Aerobic bacteria levels in blood (a) and peritoneal exudates (b) from sham or CLP-
operated mice±RvD2-Me (100 ng; i.v.) at 12h (n=5–6 per group). (c,d) Peritoneal leukocyte 
differentials (n=3–5). (e) Plasma cytokine levels (n=3–6) (f, g) Peritoneal PGE2 and LTB4 
levels. (h,i) Phagocytosis of E. coli and intracellular ROS in human PMN. (j) 12h 
temperatures of CLP-mice (k) Kaplan-Meier survival analysis of vehicle (n=13) and RvD2-
treated (n=12) CLP mice. Results are mean±s.e.m. (a-g) *P<0.05 two-tailed unpaired 
Student’s t-test, (h-j) *P<0.05 by one-way ANOVA, (k) *P<0.05 one-tailed log-rank test.
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